gonyzyf.wordpress.com
Worldwide rights to the cancer drug elesclomol will revert to which may pay GSKa low, single-digigt royalty on any potential future salesx of elesclomol, the Lexington, Mass.-based company said in a pressa release. “We appreciate GSK’s contributions to this program and understandstheir decision,” said Safi R. Synta’s CEO. The deal with Dr. Reddy'ds gives GSK (NYSE: GSK) exclusive rights to market the India-based company's drugs in all developing countriesd expectfor India. Dr.
Reddy's sells or is developing 100 branderd pharmaceuticalsin fast-growing therapeutic segments such as diabetes, oncology, gastroenterology and pain GSK has about 5,000 employees in the Raleigh-Durham
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment